FGFBP1 as a potential biomarker predicting bacillus Calmette–Guérin response in bladder cancer

FGFBP1 as a potential biomarker predicting bacillus Calmette–Guérin response in bladder cancer

Accurate prediction of Bacillus Calmette–Guérin (BCG) response is essential to identify bladder cancer (BCa) patients most likely to respond sustainably, but no molecular marker predicting BCG response is available in clinical routine. Therefore, we first identified that fibroblast growth factor bin...

Full description

Bibliographic Details
Main Authors:	Fei Li, Henghui Zhang, Yu Wang, Zhihao Yao, Kunfeng Xie, Qixin Mo, Qin Fan, Lina Hou, Fan Deng, Wanlong Tan
Format:	Article
Language:	English
Published:	Frontiers Media S.A. 2022-09-01
Series:	Frontiers in Immunology
Subjects:	bladder cancer bacillus Calmette–Guérin FGFBP1 biomarker PD-L1
Online Access:	https://www.frontiersin.org/articles/10.3389/fimmu.2022.954836/full

Similar Items

Granulomatous Hepatitis Following Intra-Vesical Instillation of Bacillus Calmette–Guérin for Treatment of Bladder Cancer
by: Elsa Alves Branco, et al.
Published: (2021-07-01)

Bacillus Calmette-Guerin Increases Base Excision Repair in Bladder Cancer Cells
by: Selçuk Keskin, et al.
Published: (2021-03-01)

Impact of intravesical Bacillus Calmette-Guérin and chemotherapy on the bladder microbiome in patients with non-muscle invasive bladder cancer
by: Christopher James, et al.
Published: (2023-04-01)

Bacillus Calmette–Guerin intravesical instillation therapy-induced urothelial necrosis of the bladder and upper urinary tract
by: Tsubasa Kondo, et al.
Published: (2022-09-01)

The natural course of bacillus Calmette-Guérin induced bladder lesions: A long-term follow-up study and systematic review
by: Chong Ma, et al.
Published: (2023-07-01)

Tuberculosis Epididymo-Orchitis Mimicking Malignancy Resulting from Intravesical Bacillus Calmette–Guérin Immunotherapy for Bladder Cancer: A Case Report of a Rare Complication
by: Liang-Wei Chiu, et al.
Published: (2022-11-01)

Childhood lupus vulgaris after Bacillus Calmette–Guérin vaccine
by: Sarah Hamdy Soliman, et al.
Published: (2023-01-01)

Establishment of an in vitro model of monocyte-like THP-1 cells for trained immunity induced by bacillus Calmette-Guérin
by: Jin-Chuan Xu, et al.
Published: (2024-04-01)

Transdifferentiation of Small Cell Carcinoma of the Urinary Bladder from Urothelial Carcinoma after Transurethral Resection of a Bladder Tumor, Intravesical Bacillus Calmette-Guerin Instillation, and Chemotherapy: A Case Report
by: Kento Morozumi, et al.
Published: (2016-11-01)

Immune Predictors of Response after Bacillus <i>Calmette–Guérin</i> Treatment in Non-Muscle-Invasive Bladder Cancer
by: Marta Rodríguez-Izquierdo, et al.
Published: (2023-11-01)

Recurrence and progression in nonmuscle invasive transitional cell carcinoma of urinary bladder treated with intravesical Bacillus Calmette–Guerin: A single center experience and analysis of prognostic factors
by: Shouki N Bazarbashi, et al.
Published: (2016-01-01)

Bladder-sparing Treatment in Patients with Bacillus Calmette-Guerin–unresponsive Non–muscle-invasive Bladder Cancer: An Analysis of Long-term Survival Outcomes
by: Wei Shen Tan, et al.
Published: (2023-07-01)

Dual Bacillus Calmette–Guerin vaccination along the border communities of Angola and Namibia
by: Abubakar Sadiq Umar, et al.
Published: (2016-01-01)

Effect of Age on Outcome of High-Risk Non-Muscle-Invasive Bladder Cancer Patients Treated with Second Transurethral Resection and Maintenance Bacillus Calmette-Guerin Therapy
by: Sümer Baltacı, et al.
Published: (2016-09-01)

OncoTherad<sup>®</sup> (MRB-CFI-1) Nanoimmunotherapy: A Promising Strategy to Treat Bacillus Calmette–Guérin-Unresponsive Non-Muscle-Invasive Bladder Cancer: Crosstalk among T-Cell CX3CR1, Immune Checkpoints, and the Toll-Like Receptor 4 Signaling Pathway
by: João Carlos Cardoso Alonso, et al.
Published: (2023-12-01)

Successful treatment of anogenital warts with single dose Bacillus Calmette Guerin vaccine without prior sensitization in tuberculosis endemic country: Two case report
by: Pati Aji Achdiat, et al.
Published: (2023-01-01)

Intravesical bacillus Calmette-Guerin (BCG) in treating non-muscle invasive bladder cancer—analysis of adverse effects and effectiveness of two strains of BCG (Danish 1331 and Moscow-I)
by: Yuvaraja B. Thyavihally, et al.
Published: (2022-04-01)

Neutrophil-to-lymphocyte ratio (NLR) during induction is a better predictor than preoperative NLR in non-muscle-invasive bladder cancer receiving Bacillus Calmette-GuÉRin
by: Deng-xiong Li, et al.
Published: (2023-03-01)

First vaccination after birth: serious adverse events of Bacillus Calmette-Guérin (BCG) in real-world
by: Jinmiao Lu, et al.
Published: (2022-11-01)

Intravesical Bacillus Calmette–Guérin Treatment for T1 High-Grade Non-Muscle Invasive Bladder Cancer with Divergent Differentiation or Variant Morphologies
by: Makito Miyake, et al.
Published: (2021-05-01)

Gluteal abscess: An unusual complication of Bacille Calmette-Guérin
by: Hakan Buyukoglan, et al.
Published: (2011-01-01)

The role of Bacillus Calmette-Guérin administration on the risk of dementia in bladder cancer patients: a systematic review and meta-analysis
by: Chao Han, et al.
Published: (2023-08-01)

Modified Glasgow Prognostic Score as a Predictor of Recurrence in Patients with High Grade Non-Muscle Invasive Bladder Cancer Undergoing Intravesical Bacillus Calmette–Guerin Immunotherapy
by: Matteo Ferro, et al.
Published: (2022-02-01)

Lessons from Bacillus Calmette-Guérin: Harnessing Trained Immunity for Vaccine Development
by: Samuel T. Pasco, et al.
Published: (2020-09-01)

Unexpected Transient Glioblastoma Regression in a Patient Previously Treated with Bacillus Calmette–Guérin Therapy: A Case Report and Immunomodulatory Effects Hypothesis
by: Gianluca Scalia, et al.
Published: (2023-11-01)

A Phase 1b Clinical Study of Intravesical Photodynamic Therapy in Patients with Bacillus Calmette-Guérin–unresponsive Non–muscle-invasive Bladder Cancer
by: Girish S. Kulkarni, et al.
Published: (2022-07-01)

Assessment of angiogenic factor, vascular endothelial growth factor, serum and urine level changes in superficial bladder tumor immunotherapy by intravesical Bacillus Calmette-Guerin
by: Kerigh Behzad, et al.
Published: (2010-01-01)

Transüretral Mesane Tümörü Rezeksiyonu Sonrası Bacillus Calmette-Guérin Bcg İmmünoterapisine Bağlı Nadir Bir Komplikasyon: Akut Solunum Yetmezliği ve Sepsis
by: Jale Bengi Çelik, et al.
Published: (2018-12-01)

GSK2656157, a PERK Inhibitor, Alleviates Pyroptosis of Macrophages Induced by Mycobacterium <i>Bacillus Calmette–Guerin</i> Infection
by: Boli Ma, et al.
Published: (2023-11-01)

Lymphocyte-to-Monocyte Ratio (LMR) During Induction Is a Better Predictor Than Preoperative LMR in Patients Receiving Intravesical Bacillus Calmette -Guerin for Non-Muscle-Invasive Bladder Cancer
by: Deng-xiong Li, et al.
Published: (2022-07-01)

Sarcopenia Predicts Disease Progression in Patients with T1 High-grade Non–muscle-invasive Bladder Cancer Treated with Adjuvant Intravesical Bacillus Calmette-Guérin: Implications for Decision-making?
by: Francesco Soria, et al.
Published: (2023-04-01)

Quality of Life in Patients with High-grade Non–muscle-invasive Bladder Cancer Undergoing Standard Versus Reduced Frequency of Bacillus Calmette-Guérin Instillations: The EAU-RF NIMBUS Trial
by: Christine G.J.I. van Straten, et al.
Published: (2023-10-01)

Delayed Diagnosis of Mycobacterium bovis bacillus Calmette-Guérin Periprosthetic Joint Infection Following Total Knee Arthroplasty
by: Christopher E. Pelt, MD, et al.
Published: (2024-06-01)

Evaluating the Protective Effect of Intravesical Bacillus Calmette-Guerin against SARS-CoV-2 in Non-Muscle Invasive Bladder Cancer Patients: A Multicenter Observational Trial
by: Rodolfo Hurle, et al.
Published: (2023-03-01)

From Interferon to Checkpoint Inhibition Therapy—A Systematic Review of New Immune-Modulating Agents in Bacillus Calmette–Guérin (BCG) Refractory Non-Muscle-Invasive Bladder Cancer (NMIBC)
by: Susanne Deininger, et al.
Published: (2022-01-01)

Effects of Bacillus Calmette-Guérin on immunometabolism, microbiome and liver diseases
by: Muhammad Umair Ijaz, et al.
Published: (2023-06-01)

Failed endovascular abdominal aortic aneurysm repair due to Mycobacterium bovis infection following intravesical bacillus Calmette-Guérin therapy
by: Masato Nishizawa, MD, PhD, et al.
Published: (2022-12-01)

Bacillus Calmette-Guérin Spondylodiscitis after Intravesical BCG Therapy: A Case Report
by: Akihito Kawai, et al.
Published: (2022-11-01)

<italic>Mycobacterium</italic> bovis Associated Aneurysm of the Common Iliac Artery After Bacillus Calmette-Guérin Intravesical Treatment for Urothelial Carcinoma
by: Davide Voci, et al.
Published: (2022-12-01)

Evolution of the Bacillus Calmette-Guérin scar Russia and Moreau strains in newborns: A brazilian cohort
by: Ramon Andrade de Souza, et al.
Published: (2023-08-01)